Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus CONRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN SODIUM versus CONRAY.
CHOLOGRAFIN SODIUM vs CONRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodipamide (cholografin sodium) is a radiographic contrast agent that opacifies the biliary ducts and gallbladder by being excreted into bile via the hepatic organic anion transporter (OATP) and then concentrated in the gallbladder. It absorbs X-rays due to its iodine content, allowing visualization of the biliary tree.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
2-3 mL of 30% solution intravenously over 1-2 minutes, repeated if necessary up to a total of 10 mL.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In severe renal impairment (CrCl < 30 mL/min), half-life may extend to 10-20 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Primarily renal excretion via glomerular filtration and tubular secretion. Approximately 70-80% of the dose is excreted unchanged in urine within 24 hours. Biliary excretion accounts for less than 10%, with fecal elimination minimal.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent